Valuation
- Market cap
- —
- Revenue TTM
- $2,090,000
- Net income TTM
- $-5,490,000
- PE ratio
- —
- Forward PE
- —
- Profit margin
- —
- Debt to equity
- —
Trading
- Volume
- 11,200
- Avg volume
- 1,938
- Day's range
- $1.20 – $1.74
- Shares out
- —
- Stochastic %K
- 32%
- Beta
- —
- Analysts
- Strong Sell
- Price target
- —
Company profile
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in...
Show more
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
- Phone
- 407 377 6695
- Website
- https://www.nutriband.com
- Address
- 121 South Orange Avenue, Suite 1500, Orlando, United States
Latest news
No headlines yet.
